. 2022 Feb 10;11(1):68–77. doi: 10.1089/jayao.2021.0034

Table 2.

Univariate Analysis of Prognostic Factors Affecting Survival Outcomes

Prognostic factors	No. of patients (N)	5-Year PFS (%)	Log-rank p value	5-Year OS (%)	Log-rank p value
Age at diagnosis
≤25 Years	86	48.8	0.42	57.9	0.69
>25 Years	76	58.8	0.42	61.8	0.69
Gender
Male	118	51.1	0.64	59.6	0.81
Female	44	60.9	0.64	59.8	0.81
Epicenter of tumor
Midline	56	45.9	0.28	53.7	0.31
Hemispheric	106	57.5	0.28	62.7	0.31
Metastasis at presentation
No	131	63.2	<0.0001	68.1	<0.0001
Yes	31	15.7	<0.0001	25.6	<0.0001
Extent of resection
GTR/NTR	101	68.7	<0.0001	74.7	<0.0001
STR	61	27.2	<0.0001	33.8	<0.0001
Risk stratification
SR	80	83.7	<0.0001	89.2	<0.0001
HR	82	23.4	<0.0001	30.8	<0.0001
Histological subtype
Non-LCA	111	60.1	<0.0001	70.5	<0.0001
LCA	26	18.8	<0.0001	15.4	<0.0001
Molecular subgrouping
WNT	14	87.5	0.01	87.5	0.03
SHH	71	55.2		62.2
Others^a	21	38.3		50.1
Interval between surgery and RT
>6 Weeks	59	44.2	0.02	46.2	0.005
≤6 Weeks	99	60.3	0.02	67.6	0.005
Adjuvant systemic chemotherapy
Yes	77	44.3	0.12	54.2	0.13
No	71	60.9	0.12	64.7	0.13

All p values ≤0.05 are considered statistically significant and highlighted in bold.

^{^a}

Others pertains to non-WNT/non-SHH molecular subgroup.

OS, overall survival; PFS, progression-free survival.